IL296927B2 - Antiviral compounds and method for treating rna viral infection, particularly covid-19 - Google Patents

Antiviral compounds and method for treating rna viral infection, particularly covid-19

Info

Publication number
IL296927B2
IL296927B2 IL296927A IL29692722A IL296927B2 IL 296927 B2 IL296927 B2 IL 296927B2 IL 296927 A IL296927 A IL 296927A IL 29692722 A IL29692722 A IL 29692722A IL 296927 B2 IL296927 B2 IL 296927B2
Authority
IL
Israel
Prior art keywords
groups
ring
alkyl
group
optionally substituted
Prior art date
Application number
IL296927A
Other languages
English (en)
Hebrew (he)
Other versions
IL296927B1 (en
IL296927A (en
Original Assignee
Senhwa Biosciences Inc
Soong Tai Sen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc, Soong Tai Sen filed Critical Senhwa Biosciences Inc
Publication of IL296927A publication Critical patent/IL296927A/en
Publication of IL296927B1 publication Critical patent/IL296927B1/en
Publication of IL296927B2 publication Critical patent/IL296927B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL296927A 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19 IL296927B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US202063053908P 2020-07-20 2020-07-20
PCT/US2021/022976 WO2021202114A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19

Publications (3)

Publication Number Publication Date
IL296927A IL296927A (en) 2022-12-01
IL296927B1 IL296927B1 (en) 2025-07-01
IL296927B2 true IL296927B2 (en) 2025-11-01

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
IL296927A IL296927B2 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19
IL296924A IL296924A (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL296924A IL296924A (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d

Country Status (11)

Country Link
US (2) US20210308137A1 (https=)
EP (2) EP4126846A1 (https=)
JP (2) JP2023520883A (https=)
KR (2) KR20230004550A (https=)
CN (1) CN116075502B (https=)
AU (2) AU2021249224A1 (https=)
BR (2) BR112022019558A2 (https=)
CA (2) CA3179167A1 (https=)
IL (2) IL296927B2 (https=)
TW (2) TW202203914A (https=)
WO (2) WO2021202114A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208792A1 (en) * 2008-02-29 2012-08-16 Cylene Pharmaceuticals, Inc. Protein kinase modulators
US8575177B2 (en) * 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
US9062043B2 (en) * 2006-09-01 2015-06-23 Senhwa Biosciences, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ｃｋ2 활성과 관련된 장애의 치료 방법
US20110071136A1 (en) * 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc Novel tricyclic protein kinase modulators
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
WO2021195126A1 (en) * 2020-03-24 2021-09-30 Burnet Michael W Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062043B2 (en) * 2006-09-01 2015-06-23 Senhwa Biosciences, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US20120208792A1 (en) * 2008-02-29 2012-08-16 Cylene Pharmaceuticals, Inc. Protein kinase modulators
US8575177B2 (en) * 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORDON DE ET AL., A SARS-COV-2-HUMAN PROTEIN-PROTEIN INTERACTION MAP REVEALS DRUG TARGETS AND POTENTIAL DRUG-REPURPOSING, 27 March 2020 (2020-03-27) *
KO M ET AL., SCREENING OF FDA-APPROVED DRUGS USING A MERS-COV CLINICAL ISOLATE FROM SOUTH KOREA IDENTIFIES POTENTIAL THERAPEUTIC OPTIONS FOR COVID-19, 2 March 2020 (2020-03-02) *
SURJIT M ET AL., THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS NUCLEOCAPSID PROTEIN IS PHOSPHORYLATED AND LOCALIZES IN THE CYTOPLASM BY 14-3-3-MEDIATED TRANSLOCATION, 30 September 2005 (2005-09-30) *

Also Published As

Publication number Publication date
CN116075502A (zh) 2023-05-05
EP4126846A1 (en) 2023-02-08
CA3179167A1 (en) 2021-10-07
AU2021249224A1 (en) 2022-12-01
IL296927B1 (en) 2025-07-01
US20210308110A1 (en) 2021-10-07
WO2021202114A1 (en) 2021-10-07
WO2021202115A1 (en) 2021-10-07
EP4126845A4 (en) 2024-05-01
US20210308137A1 (en) 2021-10-07
BR112022019554A2 (pt) 2022-12-06
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
KR20230004550A (ko) 2023-01-06
JP2023520882A (ja) 2023-05-22
TW202203915A (zh) 2022-02-01
AU2021248867A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
US11696911B2 (en) 2023-07-11
EP4126845A1 (en) 2023-02-08
KR20230004549A (ko) 2023-01-06
JP2023520883A (ja) 2023-05-22
BR112022019558A2 (pt) 2022-12-06
IL296927A (en) 2022-12-01
TW202203914A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
US9487534B2 (en) Modulators of virus assembly as antiviral agents
CN109843893B (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
EP2917184A1 (en) Alternative uses for hbv assembly effectors
CN115504968A (zh) 三嗪衍生物
US11696911B2 (en) Antiviral compounds and method for treating RNA viral infection, particularly COVID-19
WO2020143798A1 (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112118891A (zh) 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
TW202031655A (zh) 對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-吡唑并[4,3-c]吡啶脲活性劑
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
HK40086507B (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
CN110437232B (zh) 双并环脲类核衣壳抑制剂及其药物用途
CN114159445B (zh) 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用
JP7717704B2 (ja) Ｂ型肝炎ウイルスのスピロ環式阻害剤
JP7495758B2 (ja) マクロライド化合物及びその慢性呼吸器疾患の治療用途
RU2733945C2 (ru) Замещённые изоксазолы, фармацевтические композиции на их основе, обладающие противовирусной активностью, и способ их применения
CN118666868A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN114539142A (zh) 吡啶酮类化合物，其药物组合物、制备方法和应用
EP3825318A1 (en) Oxalamido-substituted tricyclic inhibitors of hepatitis b virus